News | May 31, 2021
Margins impacted by high expenses for Pfizer: ICICI Securities
Adjusted PAT declined 18.8% YoY
Adjusted PAT declined 18.8% YoY
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The company plans to enter the EU markets in FY22
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Subscribe To Our Newsletter & Stay Updated
